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We have recently shown the CD44 variant isoform
10 (CD44v10) to be expressed on reactive as well as
malignant cutaneous lymphocytes; however, the
functional consequences of CD44v10 expression on
lymphocytes are not elucidated. By using appropri-
ately transfected lymphatic cells we analyzed the role
of CD44v10 on lymphocytes in cell±matrix adhesion
and homotypic and heterotypic cell±cell adhesion
assays. Despite a low binding af®nity to hyaluronan,
CD44v10-expressing lymphocytes exhibited heteroty-
pic cell±cell adhesion to in¯amed dermal microvas-
cular endothelium and keratinocytes, as indicated by
Stamper±Woodruff assays on tissue sections of
delayed type hypersensitivity reactions and adhesion
assays with cultured keratinocytes and cytokine-
stimulated human dermal microvascular endothelial
cells. Antibody-blocking assays excluded interaction
of CD44v10 with the principal CD44 ligand hyaluro-
nan as well as involvement of selectins or integrins in
these heterotypic cell±cell adhesion assays. In con-
trast, cellular aggregation assays with ¯uorescence-
labeled CD44v10- and CD44H-expressing lympho-
cytes revealed homotypic CD44v10/CD44v10 bind-
ing as well as binding of CD44v10 with CD44H.
Heterotypic cell±cell adhesion assays with ultraviolet-
A-irradiated CD44v-negative cytokine-stimulated
endothelial cells demonstrated binding kinetics of
CD44v10-expressing lymphocytes paralleling those of
endothelial CD44H expression. These results imply
that a hyaluronan-independent CD44v10/CD44H-
mediated pathway is involved in lymphocyte in®ltra-
tion into the dermis and epidermis of in¯amed skin
and suggest modulation of CD44H expression on
in¯amed dermal microvascular endothelium as a
mechanism of ultraviolet-A-induced therapeutic
effects on the skin. Key words: heterotypic adhesion/
homotypic adhesion/transfection/UVA. J Invest Dermatol
117:949±957, 2001
C
D44 is a family of cell surface proteoglycans expressed
on a variety of cell types including T and B
lymphocytes. CD44 has been demonstrated to
represent the principal receptor of hyaluronan
(HA), and expression on lymphocytes can mediate
primary adhesion of lymphocytes to HA expressed on vascular
endothelial cells (DeGrendele et al, 1996; 1997a; 1997b). This
process is an important part of the multistep model of extravasation
of lymphocytes, necessary, for example, for the development of
targeted host responses during in¯ammatory processes (Butcher,
1991; Springer, 1994). In this context, expression of CD44 on
lymphocytes has been shown to mediate collagen-induced murine
arthritis, for example, and to be associated with the development of
human arthritis (Mikecz et al, 1995; Verdrengh et al, 1995; Estess et
al, 1998), experimental allergic encephalomyelitis, and allogeneic
graft rejection (Brocke et al, 1999; Kno¯ach et al, 1999a; 1999b).
The high expression of CD44 on lymphocytes in contact dermatitis
(Wahbi et al, 1996) and the inhibition of lymphocyte in®ltration
into cutaneous delayed type hypersensitivity (DTH) reactions in vivo
by anti-CD44 antibody (Camp et al, 1993) also implicate the
participation of CD44 in the development of both cutaneous
malignant and reactive lymphocyte in®ltrates.
The biologic functions of the CD44 receptor family are
modulated by cell-type speci®c glycosylation (Brown et al, 1991;
Jalkanen and Jalkanen, 1992) but may also be determined by
alternative splicing of 10 so-called variant exons encoding a part of
the extracellular domain of the CD44 molecule (Screaton et al,
1992). Whereas the 80±90 kDa form (commonly referred to as
CD44H), which lacks all variant exons, is the most widely
expressed isoform of CD44, the alternatively spliced CD44 variant
isoforms (CD44v) ranging from 110 kDa to over 250 kDa in size
have a much more restricted pattern of expression (Lesley et al,
1993). Insertion of variant exons into the CD44H molecule may
result in a signi®cantly lower binding af®nity to HA (Stamenkovic
et al, 1991; Jackson et al, 1995) but may also be associated with gain
of novel and sometimes unique functional properties signi®cantly
different from those observed for CD44H. For example, CD44v
isoforms containing variant exons v4±7 (CD44v4±7) or v6±7
(CD44v6±7) have been shown to confer metastatic behavior to a
rat pancreas adenocarcinoma cell line (GuÈnthert et al, 1991; Rudy et
al, 1993), CD44v3 may induce formation of bone marrow tumors
of lymphoma cells (Bartolazzi et al, 1995), CD44v8±10 may induce
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increased tumor cell growth and metastasis formation of murine
®brosarcroma cell lines (Dougherty et al, 1992), CD44v6 may
mediate homing and adhesion of multiple myeloma cells to bone
marrow stromal cells or mediate dissemination of non-Hodgkin's
lymphomas (Yakushijin et al, 1998; Asosingh et al, 2000), CD44v7
on lymphocytes has been shown to actively participate in the
maintenance of experimental colitis (Wittig et al, 2000), and CD44
variants but not CD44H may be involved in stimulating cell
motility and chemotaxis (Katagiri et al, 1999).
Most recently, we have demonstrated predominant expression of
CD44v10 on skin-in®ltrating lymphocytes of atopic dermatitis or
DTH reactions as well as of cutaneous lymphomas. Furthermore,
lymphocytes derived from SeÂzary's syndrome patients have been
shown to exhibit coexpression of CD44v10 with cutaneous
lymphocyte antigen (CLA), the so-called skin homing receptor
(Wagner et al, 1998). As the functional consequences of CD44v10
expression on lymphocytes are poorly understood, we used
appropriately transfected human lymphoid cells to examine the
functional consequences of CD44v10 expression on lymphocytes
for heterotypic cell±cell adhesion events. The results reported here
demonstrate that CD44v10 on lymphocytes mediates adhesion to
in¯amed dermal microvascular endothelial cells as well as
keratinocytes, an important prerequisite for the development of
cutaneous in¯ammatory and malignant lymphocytic diseases. In
contrast to the previously reported interaction of CD44H with
endothelial HA, CD44v10 may mediate adhesion to in¯amed
vascular endothelium preferentially by interaction with endothelial
CD44H.
MATERIALS AND METHODS
Cell lines and antibodies The human Burkitt lymphoma-derived B
cell lymphoma cell line Namalwa was obtained from the German
Collection of Microorganisms and Cell Cultures (Braunschweig,
Germany) and cultured in RPMI 1640 plus 10% fetal bovine serum
(FBS). Primary human epidermal keratinocytes and human umbilical
vein endothelial cells (HUVEC) were obtained by Promocell
(Heidelberg, Germany) and cultured in keratinocyte growth medium and
endothelial cell growth medium, respectively (Promocell). The human
dermal microvascular endothelial cell line HMEC-1 (kindly provided by
Dr. Lawley, CDC, Atlanta, GA) was cultured in endothelial basal
medium plus 10 ng per ml epidermal growth factor (Promocell), 1 mg
per ml hydrocortisone (Sigma, Deisenhofen, Germany), and 10% FBS.
Antibodies used included CD44 variant-exon-speci®c monoclonal
VFF14 and VFF16 directed against v10, anti-CD44 framework SFF2
(Bender, Vienna, Austria), anti-CD44 HA binding domain MEM-85
(Monosan/Cell Systems Biotechnology, Remagen, Germany), anti-
CD11a (aLb2 integrin/a-chain of LFA-1) MHM24, anti-CD18 (aLb2
integrin/b-chain of LFA-1) MHM23 (Dako, Hamburg, Germany), anti-
CD49d (a4b7 integrin/LPAM-1, a4b1 integrin/VLA-4) HP2/1, anti-
CD62L (L-selectin) FMC46 (Serotec/Camon, Wiesbaden, Germany),
anti-CD54 (ICAM-1) BBA20, anti-CD62E (E-selectin) BBIG-E4 (R&D
Systems), and anti-CLA (cutaneous-lymphocyte-associated antigen/car-
bohydrated P-selectin glycoprotein ligand 1) HECA-452 (Pharmingen,
San Diego, CA).
Preparation of CD44 isoform constructs and stable transfection of
Namalwa cells Polymerase chain reaction (PCR) products were
generated using cDNA obtained from a microdissected primary tumor-
stage mycosis fungoides tissue section with the following primers:
GGAAGCTTCCAGGGATCCTCCAGCTCCTTTCG (5¢ sequence,
complementary to untranslated 5¢-CD44 sequence) and GGAAGCT44G/
C/A (3¢ sequence, complementary to the poly A-tail). Each primer
contained a HindIII restriction site at its 5¢ end; the wobble in the 3¢
primer was chosen to avoid loss of CD44 transcripts due to the use of
multiple polyadenylation signals (Screaton et al, 1992). PCR products
were cloned via T/A ligation into pGEM-T vector (Promega/Serva,
Heidelberg, Germany) and single clones of transfected Escherichia coli
JM109 cells were analyzed for their respective CD44 cDNA insert by
dideoxynucleotide sequencing.
CD44H and CD44v10 cDNAs were inserted into HindIII-cut
eukaryotic expression vector pCEP4 (Invitrogen, San Diego, CA) and
transfected into Namalwa cells by electroporation (350 V per cm, 960
mF; Gene Pulser transfection apparatus, Bio-Rad, Munich, Germany).
This vector system leads to a stable episomal transfection (i.e., no
genomic integration) of the vector/insert construct. After 48 h of
growth, stable transfectants were selected for resistance to hygromycin B
(Sigma). The resultant bulk of stable transfectants was analyzed periodic-
ally for surface expression of cell adhesion molecules by ¯ow cytometric
analysis and immunostaining on cytospin preparations.
Western blot analysis, immunocytochemistry, ¯ow cytometry, and
cell sorting For western blot analysis, cells were lyzed in 1% Nonidet
P-40, 5 mM ethylenediamine tetraacetic acid, and 10 mM
phenylmethylsulfonyl ¯uoride, boiled for 5 min, resolved by 7.5%
reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis, and
electroblotted to nitrocellulose membranes (Schleicher & Schuell, Dassel,
Germany). After incubation with 5% dry milk protein in phosphate-
buffered saline (PBS), membranes were exposed to antibody SFF2 at
room temperature for 4 h, and subsequently incubated with horseradish
peroxidase conjugated goat antimouse antibody (Jackson/Dianova,
Hamburg, Germany). Signals were developed in PBS/0.5 mg per ml 4-
chloro-1-naphthol, 0.03% H2O2. Immunocytochemistry and ¯ow
cytometry were performed as described previously (Wagner et al, 1998).
For adhesion assays, CD44v10- and CD44H-expressing lymphocytes
were puri®ed by immunomagnetic bead separation (Miltenyi Biotec,
Bergisch Gladbach, Germany) with SFF2 antibody.
Cell±matrix adhesion assays to HA Twenty-four-well tissue culture
plates were prepared by coating with 5 mg per ml human umbilical cord
HA and chondroitin sulfate B overnight at 4°C. Non-speci®c binding
sites were blocked for 1 h with 1 mg per ml heat-denatured bovine
serum albumin (Sigma) in PBS (Bartolazzi et al, 1996). After vigorous
washing three times with PBS, 5 3 105 MTT-labeled sorted
lymphocytes were added and adhesion was allowed to proceed for
20 min at room temperature with or without MEM-85 (®nal dilution
1:10), VFF14, VFF16, VFF7 (isotype-matched control), and SFF2 (each
50 mg per ml) antibodies. Non-adherent cells were removed by washing
three times with PBS, and adherent cells were quanti®ed
spectrophotometrically. Adherent cells were also determined by counting
at least 20 randomly chosen microscopic ®elds (2003). All experiments
were done at least in triplicate.
Heterotypic cell±cell adhesion assays Monolayers of HMEC-1 and
HUVEC cytokine stimulated by incubation with tumor necrosis factor a
(TNF-a) and interleukin-1b (IL-1b) (titrated to give best results at
concentrations of 10 ng per ml TNF-a, 1 ng per ml IL-1b) for 48 h
(Moser et al, 1989; Brezinschek et al, 1995), and monolayer of tertiary
normal human epidermal keratinocytes were grown to subcon¯uency.
Under these conditions the endothelial cells were CD44v10 negative as
determined by immunocytochemistry on cytospin preparations. The
subcon¯uent layer was washed twice in adherence medium (RPMI 1640
plus 10% FBS) and coincubated with 2.5 3 106 in some cases MTT-
labeled sorted lymphocytes for 20 min at room temperature. Non-
adherent lymphocytes were removed by washing three times in assay
medium and under gentle rotation on a horizontal mini-shaker.
Adherent cells were quanti®ed spectrophotometrically (Bruynzeel et al,
1993) after MTT labeling or counted by microscopy. Antibody-blocking
assays were performed in the presence of MEM-85 (®nal dilution 1:10),
VFF14 and VFF16, SFF2 (each 50 mg per ml), anti-CD11a (®nal
dilution 1:10), anti-CD18 (50 mg per ml), anti-CD49d (®nal dilution
1:50), anti-CD62L (®nal dilution 1:100), anti-CD62E (20 mg per ml),
and anti-CLA (20 mg per ml) antibodies.
In addition, binding assays were performed on freshly cut frozen
human tissue sections of DTH according to Stamper and Woodruff
(Stamper and Woodruff, 1976; Salmi et al, 1995). Eight micron sections
were mounted onto glass slides and overlayed with lymphocytes (106
sorted cells per slide) resuspended in RPMI 1640. Tissue section
adhesion was performed at room temperature for 20 min on a horizontal
shaker (Hallmann et al, 1991) with or without incubation with each of
the antibodies described above. After washing three times in RPMI
1640, slides were stained with hematoxylin and eosin. To help identi®-
cation of vessels, immediately successive tissue sections were incubated
with anti-factor VIII antibody (Dako, Glastrup, Denmark) and visualized
by APAAP staining.
Heterotypic and homotypic adhesion assays of CD44v10- and
CD44H-expressing lymphocytes CD44H-expressing lymphocytes
were labeled with dye PHK2 (green ¯uorescence) and CD44v10-
expressing lymphocytes with dye PKH26 (red ¯uorescence, Sigma)
according to the manufacturer's instructions. 1.3 3 107 sorted cells were
placed in cell culture ¯asks (12.5 cm2, Falcon/Becton Dickinson,
Heidelberg, Germany) and incubated in RPMI 1640 under gentle
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rotation on a horizontal mini-shaker in the presence or absence of
MEM-85 (®nal dilution 1:10), VFF14 and VFF16, and SFF2 (each 50 mg
per ml) antibodies. After incubation, cells were examined for
spontaneous aggregation by ¯uorescence microscopy.
Modulation of CD44v10-mediated heterotypic cell±cell adhesion
by ultraviolet A (UVA) irradiation Monolayers of HMEC-1 cells
were cytokine stimulated for 48 h as described above, and subsequently
washed with PBS and irradiated with 25 J per cm2 UVA. Dosage of
UVA was titrated to give a viability of cytokine-stimulated HMEC-1
cells exceeding 95%. Sham-irradiated cytokine-stimulated HMEC-1 cells
served as controls. After irradiation, HMEC-1 cells were cultured in
RPMI 1640 and 4, 8, and 12 h later heterotypic cell±cell adhesion assays
with CD44v10-expressing lymphocytes were performed as described
above. At the same time points CD44H expression on irradiated
HMEC-1 cells was analyzed by ¯ow cytometry. Adhesion of CD44v10-
expressing lymphocytes to control-irradiated HMEC-1 cells was equated
as 100% binding.
Statistics Each of the different subgroups was described by mean and
standard deviation. To detect differences between subgroups, analysis of
variances with log-transformed data was performed. Comparisons of
single groups were done using the multiple test of Scheffe.
RESULTS
Creation of stably CD44H- and CD44v10-expressing
lymphocytes Whereas ¯ow cytometry and immunocyto-
chemistry on cytospins with antibody SFF2 revealed no
detectable constitutive expression of CD44 on parental
lymphocytes, CD44v10- and CD44H-expressing lymphocytes
exhibited staining with anti-v10 antibodies VFF14 and VFF16
and anti-framework antibody SFF2, respectively. Expression of the
expected CD44 species on transfected lymphocytes was con®rmed
by Western blot analysis at the protein level with antibody SFF2
(Fig 1) and by reverse transcriptase PCR analysis at the mRNA
level (not shown). Again, CD44 expression on parental
lymphocytes could not be detected. After immunomagnetic
sorting, CD44v10- and CD44H-expressing lymphocytes
exhibited comparable levels of cell surface CD44 molecules as
determined by ¯ow cytometry with antibody SFF2 (Fig 1). Surface
expression of integrins aLb2/LFA-1, a4b7/LPAM-1, a4b1/VLA-
4, L-selectin, and CLA/carbohydrated PSGL-1 was not detectable
on either transfected or untransfected lymphocytes by ¯ow
cytometric or immunocytochemical analysis (not shown).
Expression of exon v10 reduces the HA-binding capacity of
CD44 No parental and CD44-expressing lymphocytes adhered
to chondroitin-sulfate-coated wells (Fig 2A). Parental CD44-
negative lymphocytes also did not adhere to HA, whereas
CD44v10-expressing lymphocytes adhered to HA-coated wells
(Fig 2A). In contrast to CD44H-expressing lymphocytes, the
relative HA-binding ability of CD44v10-expressing lymphocytes
was signi®cantly reduced (p < 0.01, Fig 2A). Binding of both
CD44v10- and CD44H-expressing lymphocytes to HA was
signi®cantly diminished by preincubation of lymphocytes with
anti-HA binding domain antibody MEM-85 but not by
preincubation with antibodies SFF2 or VFF14 and VFF16,
respectively (Fig 2B).
CD44v10 mediates HA-, selectin-, and integrin-
independent heterotypic cell±cell adhesion to keratinocytes
and human dermal microvascular but not macrovascular
endothelial cells To examine the role of CD44v10 in binding
to keratinocytes and vascular endothelial cells we performed
adhesion experiments on frozen tissue sections of DTH reactions
with CD44-expressing lymphocytes. CD44v10-expressing
lymphocytes were observed to bind to the super®cial vascular
plexus of the dermis and to epidermal keratinocytes (Fig 3),
whereas binding of parental CD44-negative lymphocytes was
negligible (not shown). Adhesion of CD44v10-expressing
lymphocytes could be inhibited by preincubation with antibodies
VFF14 and VFF16 as well as SFF2 (not shown). Under the
experimental conditions chosen no adherence of CD44v10-
expressing lymphocytes to other cell types or dermal extracellular
matrix could be observed. Furthermore, blocking of CD44-
expressing lymphocytes with antibody MEM-85 did not in¯uence
lymphocyte adhesion (Fig 3). Thus, HA-independent interaction
appears to be involved in CD44v10-mediated adhesion of
lymphocytes to vascular endothelial cells and keratinocytes.
To determine the interaction of CD44v10 in binding of
lymphocytes to keratinocytes and vascular endothelial cells we
performed cell±cell adhesion assays with cultured human kerati-
nocytes, HMEC-1, and HUVEC. In contrast to parental CD44-
negative lymphocytes, CD44v10-expressing lymphocytes exhibited
strong adhesion to keratinocytes (p < 0.001, Figs 4, 5). CD44v10
mediated binding to keratinocytes at levels comparable to control
CD44H. Preincubation of lymphocytes with antibody MEM-85
did not signi®cantly affect keratinocyte adhesion of CD44v10- or
CD44H-expressing lymphocytes (Fig 5), a result consistent with
the observation ex vivo. In contrast, adhesion of lymphocytes was
Figure 1. Expression of CD44H and CD44v10 on stable
transfectants as determined by ¯ow cytometry, Western blot
analysis (upper right), and immunocytochemistry. Flow cytometry
of parental lymphoid cells (1), CD44H-transfected lymphocytes (2), and
CD44v10-transfected lymphocytes (3) (after sorting cells) with anti-
CD44 antibody SFF2. Western blot with SFF2 antibody (upper right): lane
1, parental lymphoid cells; lane 2, CD44H-transfected lymphocytes; lane
3, CD44v10-transfected lymphocytes. Molecular weights are given in
kDa. Immunocytochemistry of CD44H-transfected lymphocytes stained
with anti-CD44H antibody SFF2 (4) and of CD44v10-transfected
lymphocytes stained with anti-CD44v10 antibody VFF16 (5).
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signi®cantly reduced by incubation with antibodies VFF14 and
VFF16 (CD44v10-expressing lymphocytes, p < 0.01) and SFF2
(CD44v10-expressing lymphocytes p < 0.01, CD44H-expressing
lymphocytes p < 0.01, Fig 5). Adhesion was not affected by
incubation with anti-CD11a, anti-CD18, anti-CD49d, anti-
CD62L, anti-CD62E, and anti-CLA antibodies (not shown).
Plastic adherence was not observed.
Neither CD44-negative lymphocytes nor CD44-expressing
lymphocytes adhered to unstimulated HMEC-1 or HUVEC.
Stimulation of endothelial cells with TNF-a and Il-1b prior to
performing adhesion assays induced binding of both CD44v10- (p
< 0.001) and CD44H-expressing lymphocytes (p < 0.001, Figs 6,
7) to the dermal microvascular cell line HMEC-1 at signi®cantly
higher levels than parental CD44-negative lymphocytes. In contrast
to microvascular endothelial cells, adhesion to the macrovascular
cell line HUVEC was not observed, even after cytokine stimula-
tion. Again, binding of CD44v10 to cytokine-stimulated HMEC-1
was comparable with that of CD44H and preincubation of
lymphocytes with antibody MEM-85 did not affect CD44v10-
or CD44H-mediated adhesion to endothelial cells signi®cantly
(Fig 7). In contrast, adhesion to cytokine-stimulated HMEC-1 was
signi®cantly reduced by preincubation of CD44v10-expressing
lymphocytes with antibodies VFF14 and VFF16 (p < 0.01) as well
as SFF2 (p < 0.01) and of CD44H-expressing lymphocytes with
antibody SFF2 (p < 0.01, Fig 7). Again, preincubation with anti-
CD11a, anti-CD18, anti-CD49d, anti-CD62L, anti-CD62E, and
anti-CLA antibodies did not affect adhesion (not shown).
CD44v10 mediates adhesion to CD44H and to
CD44v10 CD44v10-expressing lymphocytes formed massive
homotypic cellular aggregates when gently agitated (Fig 8A). In
contrast, CD44H-expressing lymphocytes formed only small
cellular aggregates (Fig 8B) and parental CD44-negative
lymphocytes showed a largely monodisperse distribution with
only minor spontaneous aggregate formation of usually two to four
cells (not shown). Addition of anti-v10 antibodies VFF14 and
VFF16 and anti-framework antibody SFF2 resulted in signi®cant
inhibition of cellular aggregate formation (Fig 8D, E). Aggregation
was also observed in the presence of antibody MEM-85, thereby
excluding the possibility of exclusive recognition of HA on the
surface of target lymphocytes (not shown). Adhesion assays
performed with mixed populations of ¯uorescence-labeled
CD44v10- and CD44H-expressing lymphocytes revealed also
aggregation of CD44v10-positive lymphocytes with CD44H-
Figure 3. Adhesion of CD44v10-expressing lymphocytes to frozen
tissue sections of cutaneous DTH reaction (Stamper±Woodruff
assay). (A) Cryostat sections were incubated with CD44v10-expressing
lymphocytes as described in Materials and Methods. (B) Serial section
immunostained with anti-factor VIII antibody. Adherent cells observed
in the dermis were clustered to the super®cial dermal vascular plexus as
identi®ed by immunostaining on serial tissue sections. Adherence of
CD44v10-expressing lymphocytes can also be observed to epidermal
keratinocytes. (C) Preincubation of CD44v10-expressing lymphocytes
with anti-HA binding domain MEM-85 antibody does not result in
inhibition of frozen tissue adhesion. The results shown are representative
of three separate experiments.
Figure 2. HA-binding af®nity of CD44v10- and CD44H-
expressing lymphocytes as assessed by cell±matrix adhesion assay.
Adhesion of parental lymphoid cells (CD44±), CD44v10-transfected
lymphocytes (CD44v10+), and CD44H-transfected lymphocytes
(CD44H+) to HA-coated and chondroitin-sulfate-coated plates.
CD44v10- and CD44H-expressing lymphocytes adhere to HA-coated
plates but not to chondroitin-sulfate-coated plates. CD44±, no cell±
matrix adhesion detectable (A). Binding to HA-coated plates of
CD44v10- and CD44H-expressing lymphocytes is blocked by anti-HA
monoclonal antibody (MEM-85) (B). Adhesion expressed as mean
absorbance 6 SD of ®ve replicate experiments. Replicate assays were
performed with sorted cells. CD44±, no cell±matrix adhesion detectable.
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positive lymphocytes (Fig 8C). Aggregation between untransfected
cells and CD44H- and CD44v10-positive lymphocytes could not
be observed. These results demonstrate that CD44v10 on
lymphocytes can mediate adhesion to CD44v10 as well as CD44H.
CD44v10-mediated heterotypic cell±cell adhesion correlates
with CD44H expression on dermal microvascular
endothelial cells About 80% of the human microvascular
endothelial cells stimulated with TNF-a and IL-1b for 48 h
expressed CD44H as measured by ¯ow cytometry. CD44H
expression was signi®cantly reduced 4 h after UVA irradiation
with 25 J per cm2 and reconstituted within 8±12 h after irradiation
(Fig 9). Expression levels of integrin CD54 and selectin CD62E ±
previously reported to be modulated by UVA irradiation on
endothelial cells (Heckmann et al, 1994) ± did not differ between
irradiated and control-irradiated HMEC-1 cells (not shown).
At a comparable kinetic, adhesion of CD44v10-expressing
lymphocytes to cytokine-stimulated HMEC-1 cells was modulated
by UVA irradiation (Fig 10). In contrast to control-irradiated
HMEC-1 cells, adhesion to UVA-irradiated endothelial cells was
signi®cantly reduced 4 h after irradiation. Again, within 8±12 h
after UVA irradiation adhesion levels reconstituted again to those
obtained with control-irradiated HMEC-1 cells (Fig 10).
DISCUSSION
In this study we have demonstrated that (i) CD44v10 on
lymphocytes can mediate adhesion to in¯amed dermal micro-
vascular cells as well as to keratinocytes; (ii) CD44v10 expressed on
lymphocytes retains HA-binding af®nity but at levels signi®cantly
reduced compared with CD44H; (iii) CD44v10-mediated binding
of lymphocytes to in¯amed dermal microvascular cells and
keratinocytes is independent of the principal ligand of CD44,
HA; and (iv) CD44v10-mediated binding of lymphocytes is
mediated by interaction with CD44H expressed on in¯amed
dermal microvascular endothelium instead. Taken together, these
results indicate that expression of CD44v10 as reported on skin-
in®ltrating lymphocytes of atopic dermatitis or DTH reactions as
well as of cutaneous lymphomas (Wagner et al, 1998) may mediate
adhesive interactions required for the development of cutaneous
lymphocyte in®ltrates.
Participation in the multistep process of lymphocyte cell
adhesion to and migration through vascular endothelium
(Butcher, 1991; Springer, 1994; DeGrendele et al, 1996; Uksila et
al, 1997; Nandi et al, 2000; Siegelman et al, 2000) as well as
participation in lymphocyte cell adhesion to keratinocytes
(Bruynzeel et al, 1993) are key features of functional properties
mediated by CD44 on lymphocytes. As cell-binding properties
observed in vitro may correlate well with the in vivo homing
capacity of lymphocytes in animal models (Butcher et al, 1989), we
®rst attempted to determine the potential binding sites of
CD44v10-expressing lymphocytes in the skin by performing
Stamper±Woodruff assays on cryosections of cutaneous DTH
reactions. Our results indicate that indeed CD44v10-expressing
lymphocytes in the skin adhere to in¯amed cutaneous micro-
Figure 4. Heterotypic cell±cell adhesion of CD44v10- and
CD44H-expressing lymphocytes to cultured human epidermal
keratinocytes. Heterotypic cell±cell adhesion of CD44± lymphoid cells
(a), CD44H-positive lymphocytes (b), and CD44v10-expressing
lymphocytes (c). Adhesion assays were performed as described in Materials
and Methods.
Figure 5. Quantitative assessment of heterotypic cell±cell
adhesion of CD44v10- and CD44H-expressing lymphocytes to
human epidermal keratinocytes. Quanti®cation of heterotypic cell±
cell adhesion binding of MTT-labeled CD44± lymphoid cells (CD44±),
CD44H-positive lymphocytes (CD44H+), and CD44v10-expressing
lymphocytes (CD44v10+). Antibody-blocking assays (6 anti-v10 VFF16,
anti-CD44 framework SFF2, and anti-HA binding domain MEM-85
antibodies) were performed as described in Materials and Methods.
Blocking assays by antibodies directed against CD11a, CD18, CD49d,
CD62L, Cd62E, and CLA had no in¯uence on the heterotypic adhesion
(not shown). Adhesion expressed as the mean absorbance 6 SD of
quadruplicate determinations with sorted cells.
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vascular endothelial cells as well as keratinocytes. These results
could be supported further by in vitro heterotypic cell±cell adhesion
assays demonstrating binding of CD44v10-positive lymphocytes to
cultured human epidermal keratinocytes and cytokine-stimulated
human dermal microvascular endothelial cells.
The principal receptor of CD44, HA (Aruffo et al, 1990), is the
predominant extracellular matrix component of dermis and
epidermis and thus may play a key role in the control of
lymphocyte in®ltration into the skin. More speci®cally, CD44/
HA-mediated interactions have been implicated in the multistep
process of lymphocyte cell adhesion to and migration through
vascular endothelium (DeGrendele et al, 1996; Uksila et al, 1997;
Nandi et al, 2000; Siegelman et al, 2000). We therefore analyzed the
HA-binding capacity of CD44v10-expressing lymphocytes. The
retention of signi®cant HA-binding capacity of CD44v10 as
observed in our cell±matrix adhesion studies is consistent with
previous HA-binding studies of soluble CD44v10 containing
immunoglobulin fusion proteins (Bennett et al, 1995) and the
identi®cation of CD44v10 as an HA-binding site in vascular
endothelial cells (Lokeshwar et al, 1996). Our studies indicate also,
however, that the binding af®nity of CD44v10 on lymphocytes is
signi®cantly reduced compared with that mediated by CD44H.
Even this observation correlates well with reports on CD44v
isoforms describing a considerably lower binding af®nity for HA
than CD44H (Stamenkovic et al, 1991; Jackson et al, 1995). Several
but not all of the CD44-mediated lymphocyte functions including
lymph node homing, progenitor cell homing, lymphopoiesis, and
tumor growth enhancement have been attributed to its HA-
binding capacity (Aruffo et al, 1990; Miyake et al, 1990;
Stamenkovic et al, 1991; Sy et al, 1991; Bartolazzi et al, 1994;
Zhang et al, 1995; Vogt Sionov and Naor, 1997), and indeed,
despite their signi®cantly reduced HA-binding capacity, CD44v10-
expressing lymphocytes exhibited heterotypic cell±cell adhesion to
in¯amed microvascular endothelium and keratinocytes at levels
comparable to that observed for CD44H-positive lymphocytes.
Furthermore, preincubation of lymphocytes with anti-CD44 HA
binding domain antibody MEM-85 did not signi®cantly alter
CD44v10-mediated cell adhesion to either tissue sections in
Stamper±Woodruff assays or target cells in heterotypic in vitro
cell±cell adhesion assays. Taken together these results strongly
imply an HA-independent binding mechanism of CD44v10-
expressing lymphocytes with recognition of a cellular ligand other
than HA.
Selectin- or integrin-mediated pathways of cell adhesion have
been previously suggested to be activated in lymphocytes via CD44
(Koopman et al, 1990; Bruynzeel et al, 1993). Most recently,
Siegelman et al demonstrated in in vivo and in vitro studies that
primary adhesive events mediated by CD44 expressed on
lymphocytes may be followed by ®rm adhesion of lymphocytes
using the integrin VLA-4/VCAM-1 pathway (Siegelman et al,
2000). Flow cytometric analysis of the CD44v10-expressing
lymphocytes used in our assays, however, did not reveal expression
of cellular adhesion molecules of the selectin or integrin families.
Furthermore, lack of signi®cant inhibition of CD44v10-mediated
lymphocyte adhesion to in¯amed microvascular endothelial cells as
Figure 6. Heterotypic cell±cell adhesion of CD44v10- and
CD44H-expressing lymphocytes to TNF-a- and Il-1b-stimulated
human dermal microvascular endothelial cells. Heterotypic cell±cell
adhesion of CD44± lymphoid cells (a), CD44H-positive lymphocytes (b),
and CD44v10-expressing lymphocytes (c). Adhesion assays were
performed as described in Materials and Methods.
Figure 7. Quantitative assessment of heterotypic cell±cell
adhesion to TNF-a- and IL-1b-stimulated human dermal
microvascular endothelial cells. Quanti®cation of heterotypic cell±cell
adhesion binding of MTT-labeled CD44± lymphoid cells (CD44±),
CD44H-positive lymphocytes (CD44H+), and CD44v10-expressing
lymphocytes (CD44v10+). Antibody-blocking assays (6 anti-v10 VFF16,
anti-CD44 framework SFF2, and anti-HA binding domain MEM-85
antibodies) were performed as described in Materials and Methods.
Blocking assays by antibodies directed against CD11a, CD18, CD49d,
CD62L, Cd62E, and CLA had no in¯uence on the heterotypic adhesion
(not shown). Adhesion expressed as the mean absorbance 6 SD of
quadruplicate determinations with sorted cells.
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well as keratinocytes by anti-selectin and anti-integrin antibodies
strongly argues against the induction or participation of integrin- or
selectin-mediated pathways of cell adhesion at least in our assays.
CD44v isoforms in particular have been described to form
homoaggregates at the cell surface (Sleeman et al, 1996) that may,
for example, induce also the formation of large homotypic
aggregates when expressed on lymphoid cells (Yakushijin et al,
1998). Consistent with these reports, cellular aggregation assays in
our study demonstrate formation of homotypic cellular aggregates
of lymphocytes induced by CD44v10 to a greater degree than those
induced by CD44H. Furthermore, our results demonstrate that
CD44v10 on lymphocytes can mediate also formation of large
cellular aggregates with CD44H-expressing lymphocytes. These
results indicate that CD44v10 has the potential to homotypically
bind not only to CD44v10 itself but also to CD44H molecules.
Our results further suggest that binding of CD44v10-positive
Figure 8. Homotypic cell±cell adhesion assays performed with
CD44v10- and CD44H-expressing lymphocytes. (A) Homotypic
cell±cell aggregation of PKH26-labeled CD44v10-expressing
lymphocytes (red ¯uorescence). (B) Corresponding aggregation assay
performed with PKH2-labeled CD44H-expressing lymphocytes (green
¯uorescence). (C) Mixed incubation of CD44v10-expressing
lymphocytes (red ¯uorescence) with CD44H-expressing lymphocytes
(green ¯uorescence). Overlying signals indicating CD44v10/CD44H
aggregation result in yellow ¯uorescence. (D) Inhibition of homotypic
cell±cell aggregation of CD44H-expressing lymphocytes by antibody
blocking with anti-CD44 framework SFF2. (E) Inhibition of homotypic
cell±cell aggregation of CD44v10-expressing lymphocytes by antibody
blocking with anti-CD44v10 VFF16.
Figure 9. UVA modulation of CD44H expression on cytokine-
stimulated human dermal microvascular endothelial cells.
Expression of CD44H on cytokine-stimulated HMEC-1 cells before and
at different time points after UVA irradiation with 25 J per cm2 as
determined by ¯ow cytometry with SFF2 antibody. Reduction of
CD44H expression on irradiated HMEC-1 cells was calculated based on
the level of expression of control-irradiated HMEC-1 cells equal to
100%. Fluorescence-activated cell sorter results of a representative
experiment are shown.
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lymphocytes may occur to CD44H not only expressed on
lymphatic cells but also expressed on in¯amed dermal microvascular
endothelium. UVA irradiation is an established therapeutic strategy
to suppress lymphocyte-mediated skin diseases and has been shown
to modify expression of cell adhesion molecules on endothelial
cells, especially integrin CD54 and selectin CD62E (Heckmann et
al, 1994). After UVA irradiation of cytokine-stimulated human
dermal microvascular endothelial cells we could observe signi®cant
reduction of endothelial CD44H expression within 4 h with
recovery to preirradiation expression levels within 8±12 h.
Whereas these experiments give no direct proof for CD44±CD44
self interactions, the lack of CD44v10 expression on endothelial
cells and the comparable kinetics in reduction of CD44H
expression on endothelial cells and reduction of cell±cell adhesion
to endothelial cells after UVA irradiation argue for an involvement
of CD44v10/CD44H-mediated adhesion of lymphocytes to
in¯amed dermal microvascular endothelium.
The identi®cation of molecules that are critically involved in the
development of reactive and malignant lymphocytic skin diseases
may give new insights into the underlying pathophysiologic
mechanisms, may lead to a more detailed understanding of
established therapeutic strategies, and may provide the basis for
the development of novel, speci®cally receptor-targeted thera-
peutic strategies. Taken together, the results of our study indicate
that expression of CD44v10 confers novel adhesive characteristics
to lymphatic cells that seem to be unrelated to HA-binding
capacity, demonstrate for the ®rst time that CD44v10-mediated
interactions of lymphocytes with in¯amed dermal microvascular
endothelium may be correlated with its binding capacity to
endothelial CD44H, and suggest modulation of CD44H expression
on in¯amed dermal microvascular endothelium to represent a
mechanism of UVA-induced therapeutic effects on skin.
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